GenSight Biologics Investor Relations Material

GenSight Biologics SA is a French biotechnology company focused on developing gene therapies for neurodegenerative diseases affecting vision. The company's primary area of research involves treatments for inherited retinal diseases, including Leber Hereditary Optic Neuropathy (LHON), a condition that leads to sudden vision loss. GenSight Biologics uses proprietary gene therapy platforms to target and potentially restore function in damaged retinal cells. Its therapies are designed to offer long-lasting effects with a single administration. The company is headquartered in Paris, France, and its shares are listed on Euronext Paris.